A Pipeline Built to Change What’s
Possible for Genetic and Rare Diseases
Our programs are powered by STELLAR™ — a non-viral delivery platform engineered for safety, durability, and repeat dosing.
Lead Program
Cystic Fibrosis (CF) – Phase 2b Ready
Key Points:
Mutation-agnostic approach restoring natural CFTR function
FDA Orphan Drug Designation
Positive human Phase I/II data
Registration-oriented Phase 2b planned
Primary Focus Area
Rare Disease Programs
| Indication | Stage | Notes |
| Stargardt’s Disease | IND-Enabling | FDA Orphan Designation |
| Additional Rare Genetic Disorders | Preclinical | STELLAR™ validated in relevant tissues |
Our rare disease programs reflect the strengths of non-viral delivery —
especially in tissues where repeat dosing and long-term expression are critical.
Secondary Tier
Other Early-Stage Programs
Parkinson’s Disease
Diabetic Retinopathy
Opioid Use Disorder
These programs demonstrate the versatility of STELLAR™ across neurological, ophthalmic, and systemic conditions.
Partnering Opportunities
Copernicus is open to collaborations that expand the reach of the
STELLAR™ platform across therapeutic areas.